GlassScriptPhysician profile
Amina N Husain
NPI 1902890288
$1,608.14
in general payments reported to CMS, 2019-2025
20 companies · $701 in 2025
The $701 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $58.58 · 2022: $179 · 2023: $246 · 2024: $264 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $500.04 | 2022-2025 | Azstarys |
| Ars Pharmaceuticals Operations, INC. | $239.52 | 2025 | Neffy |
| Kaleo, INC. | $181.91 | 2019-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $90.48 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $71.48 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $62.49 | 2023-2024 | |
| Cranial Technologies, INC | $59.67 | 2019-2024 | Doc Band |
| Seqirus USA INC | $59.06 | 2019-2025 | Flucelvax |
| Pfizer INC. | $50.31 | 2019-2023 | |
| Tris Pharma INC | $45.17 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $40.69 | 2024 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $31.61 | 2025 | Jornay Pm |
| Cumberland Pharmaceuticals, INC. | $30.84 | 2022-2023 | Kristalose |
| Ultragenyx Pharmaceutical INC. | $25.56 | 2024 | Crysvita |
| Mayne Pharma Commercial LLC | $24.76 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.99 | 2025 | Elaprase |
| Bavarian Nordic A/S | $22.22 | 2025 | Vivotif |
| Verrica Pharmaceuticals INC. | $18.57 | 2025 | Ycanth |
| Aytu Biopharma, INC. | $17.08 | 2025 | |
| Phadia US INC. | $13.69 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amina Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.